Vita Coco (COCO) Insider Executes Option Exercises, 20,000-Share Sales via 10b5-1
Rhea-AI Filing Summary
Charles van Es, Chief Sales Officer of Vita Coco Company, Inc. (COCO), reported multiple transactions on 09/17/2025 under a Rule 10b5-1 plan. He purchased 20,000 shares via option exercises at a stated exercise price of $10.178 per share (reported as two non-qualified option exercises of 10,000 shares each) and sold 20,000 shares in Rule 10b5-1 plan transactions at a weighted average price of $42.04 per share (sales occurred across prices ranging from $42.00 to $42.19 and $42.00 to $42.18 as disclosed). Following the reported non-derivative transactions, his direct beneficial ownership figures listed are 94,328 shares and 84,328 shares on the lines reported.
Table II shows multiple outstanding non-qualified stock options at various exercise prices and vesting schedules, including currently exercisable options and several tranches that vest over future years, totaling significant option-based potential ownership.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider exercised low-strike options and sold shares through a 10b5-1 plan; transactions appear routine and not an unusual market signal.
The filing documents option exercises at a $10.178 strike and concurrent sales under a 10b5-1 plan at a weighted average of $42.04, indicating the reporting person monetized a portion of equity while retaining meaningful direct and derivative holdings. The mix of exercises and planned sales is consistent with liquidity-taking rather than an emergent negative view of company prospects. Outstanding option tranches with multi-year vesting preserve future upside sensitivity to the share price.
TL;DR: Transactions were disclosed and executed under a written 10b5-1 plan; filings include appropriate vesting and exercisability details.
The Form 4 indicates compliance with Rule 10b5-1 for sales, and provides vesting schedules and exercisability statements for multiple option grants. The reporting includes weighted-average sale price ranges and an undertaking to provide additional per-price breakdowns on request, which supports transparency. No prohibited insider trading indicators or amendments are shown in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $10.178 | $102K |
| Sale | Common Stock | 10,000 | $42.04 | $420K |
| Exercise | Common Stock | 10,000 | $10.178 | $102K |
| Sale | Common Stock | 10,000 | $42.04 | $420K |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.18, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The stock option is fully vested and currently exercisable. The stock option is fully vested and currently exercisable. The stock option vests in four equal annual installments beginning on November 27, 2022. The stock option vests in three equal annual installments beginning on August 15, 2025. The stock option vests in four equal annual installments beginning on March 10, 2024. The stock option vests in four equal annual installments beginning on March 4, 2025. The Reporting Person was granted stock options that will vest in four annual equal installments on each anniversary of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
